Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: CORO1C

Gene summary for CORO1C

Gene summary.

Gene information	Species	Human
	Gene symbol	CORO1C
	Gene ID	23603
	Gene name	coronin 1C
	Gene Alias	HCRNN4
	Cytomap	12q24.11
	Gene Type	protein-coding
	GO ID	GO:0000902
	UniProtAcc	Q9ULV4

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
23603	CORO1C	LZE2T	Human	Esophagus	ESCC	3.22e-02	3.21e-01	0.082
23603	CORO1C	LZE4T	Human	Esophagus	ESCC	5.24e-14	4.73e-01	0.0811
23603	CORO1C	LZE5T	Human	Esophagus	ESCC	1.88e-04	-1.09e-01	0.0514
23603	CORO1C	LZE8T	Human	Esophagus	ESCC	3.77e-03	2.02e-01	0.067
23603	CORO1C	LZE22T	Human	Esophagus	ESCC	2.61e-09	2.54e-01	0.068
23603	CORO1C	LZE24T	Human	Esophagus	ESCC	4.27e-12	3.33e-01	0.0596
23603	CORO1C	LZE6T	Human	Esophagus	ESCC	1.37e-06	-3.52e-02	0.0845
23603	CORO1C	P1T-E	Human	Esophagus	ESCC	2.94e-02	1.16e-01	0.0875
23603	CORO1C	P2T-E	Human	Esophagus	ESCC	3.50e-17	4.27e-01	0.1177
23603	CORO1C	P4T-E	Human	Esophagus	ESCC	8.33e-15	5.51e-01	0.1323
23603	CORO1C	P5T-E	Human	Esophagus	ESCC	5.02e-24	4.94e-01	0.1327
23603	CORO1C	P8T-E	Human	Esophagus	ESCC	2.85e-11	1.84e-01	0.0889
23603	CORO1C	P9T-E	Human	Esophagus	ESCC	2.66e-12	2.21e-01	0.1131
23603	CORO1C	P10T-E	Human	Esophagus	ESCC	2.51e-13	-1.47e-02	0.116
23603	CORO1C	P11T-E	Human	Esophagus	ESCC	4.91e-16	4.76e-01	0.1426
23603	CORO1C	P12T-E	Human	Esophagus	ESCC	2.11e-19	4.40e-01	0.1122
23603	CORO1C	P15T-E	Human	Esophagus	ESCC	4.28e-20	5.45e-01	0.1149
23603	CORO1C	P16T-E	Human	Esophagus	ESCC	1.30e-10	2.41e-01	0.1153
23603	CORO1C	P17T-E	Human	Esophagus	ESCC	3.52e-02	4.49e-01	0.1278
23603	CORO1C	P20T-E	Human	Esophagus	ESCC	6.63e-23	6.58e-01	0.1124

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000193326	Skin	cSCC	negative regulation of protein phosphorylation	123/4864	342/18723	2.48e-05	2.82e-04	123
GO:005134829	Skin	cSCC	negative regulation of transferase activity	100/4864	268/18723	2.60e-05	2.94e-04	100
GO:001076925	Skin	cSCC	regulation of cell morphogenesis involved in differentiation	43/4864	96/18723	5.00e-05	5.18e-04	43
GO:1900024110	Skin	cSCC	regulation of substrate adhesion-dependent cell spreading	28/4864	57/18723	1.47e-04	1.32e-03	28
GO:000716024	Skin	cSCC	cell-matrix adhesion	85/4864	233/18723	2.43e-04	1.98e-03	85
GO:003134622	Skin	cSCC	positive regulation of cell projection organization	120/4864	353/18723	4.49e-04	3.44e-03	120
GO:190274517	Skin	cSCC	positive regulation of lamellipodium organization	19/4864	37/18723	8.42e-04	5.81e-03	19
GO:190274316	Skin	cSCC	regulation of lamellipodium organization	25/4864	54/18723	1.00e-03	6.76e-03	25
GO:0034446110	Skin	cSCC	substrate adhesion-dependent cell spreading	43/4864	108/18723	1.12e-03	7.36e-03	43
GO:0006469110	Skin	cSCC	negative regulation of protein kinase activity	74/4864	212/18723	2.36e-03	1.37e-02	74
GO:001077121	Skin	cSCC	negative regulation of cell morphogenesis involved in differentiation	9/4864	14/18723	2.87e-03	1.60e-02	9
GO:190002521	Skin	cSCC	negative regulation of substrate adhesion-dependent cell spreading	9/4864	14/18723	2.87e-03	1.60e-02	9
GO:0033673110	Skin	cSCC	negative regulation of kinase activity	81/4864	237/18723	2.95e-03	1.64e-02	81
GO:001076110	Skin	cSCC	fibroblast migration	21/4864	47/18723	4.20e-03	2.21e-02	21
GO:003152910	Skin	cSCC	ruffle organization	24/4864	56/18723	4.44e-03	2.29e-02	24
GO:001063125	Skin	cSCC	epithelial cell migration	115/4864	357/18723	4.64e-03	2.37e-02	115
GO:0060491110	Skin	cSCC	regulation of cell projection assembly	65/4864	188/18723	5.34e-03	2.69e-02	65
GO:19000278	Skin	cSCC	regulation of ruffle assembly	15/4864	31/18723	6.02e-03	2.95e-02	15
GO:009013225	Skin	cSCC	epithelium migration	115/4864	360/18723	6.20e-03	3.04e-02	115
GO:0120032110	Skin	cSCC	regulation of plasma membrane bounded cell projection assembly	64/4864	186/18723	6.40e-03	3.13e-02	64

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

CORO1C

SNV

Missense_Mutation

c.803C>T

p.Ala268Val

p.A268V

Q9ULV4

protein_coding

tolerated(0.08)

benign(0.052)

TCGA-A7-A0CE-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

CORO1C

SNV

Missense_Mutation

c.374N>G

p.Ser125Cys

p.S125C

Q9ULV4

protein_coding

deleterious(0.03)

benign(0.049)

TCGA-A8-A06Q-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

CORO1C

SNV

Missense_Mutation

c.1531N>G

p.Gln511Glu

p.Q511E

Q9ULV4

protein_coding

deleterious(0.04)

benign(0.127)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

CORO1C

SNV

Missense_Mutation

c.1323N>G

p.Ile441Met

p.I441M

Q9ULV4

protein_coding

tolerated(0.54)

benign(0.092)

TCGA-AO-A0J9-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

CORO1C

SNV

Missense_Mutation

novel

c.106N>A

p.His36Asn

p.H36N

Q9ULV4

protein_coding

tolerated_low_confidence(0.17)

benign(0)

TCGA-E9-A5UO-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

CORO1C

insertion

In_Frame_Ins

novel

c.938_939insCAGACTTGTCTCTGGTTTCTTACAGGGTGACAGCAGTAT

p.His313_Glu314insArgLeuValSerGlyPheLeuGlnGlyAspSerSerIle

p.H313_E314insRLVSGFLQGDSSI

Q9ULV4

protein_coding

TCGA-A2-A0D2-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

CORO1C

insertion

Nonsense_Mutation

novel

c.1256_1257insTAAATGAAGATAAGATATTTATTCCATCCATGTAT

p.Gly420LysfsTer2

p.G420Kfs*2

Q9ULV4

protein_coding

TCGA-BH-A0EE-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

docetaxel

CORO1C

SNV

Missense_Mutation

novel

c.59N>A

p.Arg20His

p.R20H

Q9ULV4

protein_coding

deleterious_low_confidence(0.01)

benign(0)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

CORO1C

SNV

Missense_Mutation

rs762661543

c.1270N>A

p.Ala424Thr

p.A424T

Q9ULV4

protein_coding

deleterious(0.01)

possibly_damaging(0.742)

TCGA-EA-A410-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

CORO1C

SNV

Missense_Mutation

c.790N>A

p.Glu264Lys

p.E264K

Q9ULV4

protein_coding

deleterious(0.01)

possibly_damaging(0.479)

TCGA-EK-A2RJ-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1